Search clinical trials for: TIV

Total 6845 results

Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

Seasonal Influenza

Colombia, Mexico, Panama, Philippines
Butantan Institute
Butantan Foundation

Active, not recruiting

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

Influenza, Human

Brazil
McGill University Health Centre/Research Institute...
The Arthritis Society, Canada

Unknown

Standard Versus High Dose Inactivated Influenza Vaccine in RA (IV-RA)

Rheumatoid Arthritis

Canada
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

Influenza, Human

Korea, Republic of
University of Oxford

Completed

ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses

Influenza

United Kingdom
Novartis Vaccines

Completed

A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

Influenza

Italy, Spain
Canadian Immunization Research Network
CHU de Quebec-Universite Laval; McGill University Health Centre/Research Institute... and other collaborators

Completed

CT18 Infant Influenza Priming Study in Vaccine Naive Infants

Influenza

Canada
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011

Influenza
PT Bio Farma

Completed

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Safety Issues

Indonesia
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Influenza
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Novartis Pharmaceuticals

Terminated

Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (ELIXIR)

Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis

Germany
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
C. R. Bard

Completed

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Vascular Access Complication

United States
Il-Yang Pharm. Co., Ltd.

Completed

Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults

Influenza, Human
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above

Influenza

Czech Republic, Philippines, South Africa, Thailand
Novartis Vaccines

Completed

Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Influenza

Lithuania
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
University of Oxford

Completed

A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine

Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Influenza

United States, Colombia, Panama, Philippines
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

Influenza

Poland
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010

Influenza
MedImmune LLC
University of Pittsburgh; Passport Health

Completed

Assessing Choice in the Employer Setting (ACES) Study (MA181)

Healthy

United States
BioNTech SE
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

COVID-19 | Influenza, Human

United States
BiondVax Pharmaceuticals ltd.

Completed

Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

Influenza

Israel
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Shanghai Public Health Clinical Center

Unknown

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

HIV

China
MedImmune LLC

Completed

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Influenza

United States
Boehringer Ingelheim

Completed

Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers

Healthy
Novavax

Completed

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children

Respiratory Tract Infections

Spain, Israel
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma

Asthma

Belgium
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Emory University

Completed

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

Influenza

United States
MedImmune LLC

Completed

A Post Marking Study to Evaluate the Safety of FluMist in Children

Healthy

United States
Medtronic Cardiovascular

Active, not recruiting

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial (SMART)

Aortic Valve Stenosis | Aortic Valve Replacement | Symptomatic Aortic Stenosis

United Kingdom, United States, Netherlands, Canada, Israel, Spain, Finland, Denmark, France, Germany, Switzerland, Italy, Portugal
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

Influenza

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
Boehringer Ingelheim

Completed

Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers

Healthy
Novavax
Department of Health and Human Services

Completed

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Influenza

United States
BiondVax Pharmaceuticals ltd.

Completed

Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (BVX006)

Influenza

Israel
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

Influenza

United States
Sanofi

Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

Influenza | Flu

China

3

Subscribe